📄 genetic and genomic medicine

Uncovering the Genetic Architecture of Optic Nerve Integrity Estimates through Genome-wide Association Study Meta-analyses

This study presents the first genome-wide association meta-analyses of optic nerve integrity biomarkers in over 25,000 participants, identifying numerous novel genetic loci and prioritizing IOP-independent candidate genes like NMNAT2 and TRIOBP as potential therapeutic targets for glaucoma.

Original authors: Aman, A. M., Diaz-Torres, S., Lee, S. S.-Y., Driessen, S. J., de Vries, V. A., van der Heide, F. C. T., Kolovos, A., Schmidt, J. M., Marshall, H. N., Saleh, L., Schulze, A., Blokland, G. A., Webers, C

Published 2026-02-06

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Aman, A. M., Diaz-Torres, S., Lee, S. S.-Y., Driessen, S. J., de Vries, V. A., van der Heide, F. C. T., Kolovos, A., Schmidt, J. M., Marshall, H. N., Saleh, L., Schulze, A., Blokland, G. A., Webers, C. A. B., van der Kallen, C. J. H., Wesselius, A., Arts, I., van Asten, F., Gorski, M., Zimmermann, M. E., Stark, K. J., Heid, I. M., Young, T. L., Pasquale, L. R., Segre, A. V., Wiggs, J. L., Khawaja, A. P., Hewitt, A. W., Schuster, A. K., Berendschot, T. T. J. M., Thiadens, A. A. H. J., van Garderen, K. A., Klaver, C. C. W., Hysi, P. G., Hammond, C. J., Brandl, C., Craig, J. E., Ramdas, W. D., Ma

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: Mapping the "Wiring" of the Eye

Imagine your eye is like a high-tech camera. The optic nerve is the thick cable that sends the photos from the camera to the brain's computer. If this cable gets damaged, the pictures get blurry or disappear forever. This damage is called glaucoma.

Currently, doctors treat glaucoma by lowering the pressure inside the eye (like letting air out of a balloon) to stop the cable from getting squashed. But sometimes, even when the pressure is low, the cable still frays and breaks. Scientists want to know: Why does the cable break even when the pressure is fine?

This study is like a massive genetic detective hunt. The researchers looked at the DNA of nearly 26,000 people to find the specific "instruction manuals" (genes) that determine how thick and strong that optic nerve cable is.

The Two Main Measurements: The "Ruler" and the "Rim"

To measure the health of the optic nerve cable, the researchers used a special camera (OCT) to take two types of measurements:

The Wire Bundle (pRNFL): Think of the optic nerve as a bundle of fiber-optic wires. The researchers measured the thickness of the layer of wires right around the optic disc. If this layer gets thin, it means wires are dying.
The Tire Rim (BMO-MRW): Imagine the optic nerve head is a tire. The "rim" is the solid rubber part holding the tire together. The researchers measured the width of this rim. A thinner rim means the tire is wearing out.

What They Found: The Genetic "Blueprints"

The team scanned the DNA of thousands of people and found 38 new locations in the human genome (called "loci") that act like switches controlling the thickness of these nerve layers.

The Global View: They found 9 genetic switches that control the overall thickness of the wire bundle and 9 that control the overall width of the tire rim.
The Sector View (The "Map"): The optic nerve isn't just one big circle; it's divided into six slices (like a pizza: top, bottom, left, right, etc.). The researchers found that some genetic switches only affect specific slices.
- The "Pizza Slice" Surprise: One gene, called SIX6, was found to make the "top" slice of the nerve thicker but the "bottom" slice thinner (or vice versa). Because these effects canceled each other out when looking at the whole nerve, this gene was missed in previous studies that only looked at the "whole pie." This study showed that different parts of the nerve have their own unique genetic rules.

The Pressure Question: Is it the Balloon or the Wire?

A major question in glaucoma is: Does the nerve break because the pressure is too high (the balloon is too tight), or is the wire just naturally weak?

The Pressure Test: The researchers used a statistical method to see if the genes they found were just about eye pressure.
The Result: They found that many of these genes control the nerve's health independently of pressure.
- Analogy: Imagine two cars. Car A breaks because it's being driven too fast (high pressure). Car B breaks because its engine was built with a weak part (genetics), even if it's driven slowly. This study found the "weak parts" in the engine that exist even when the car is idling.

The "Gold Medal" Genes: Potential Drug Targets

The researchers zoomed in on the genes that seemed to protect the nerve without being influenced by pressure. They highlighted two specific genes that look very promising for future treatments:

NMNAT2: This gene is like a battery charger for the nerve cells. It helps produce energy (NAD+) that keeps the cells alive and protects them from stress. The study found that people with better versions of this gene have healthier nerves.
- Real-world connection: The paper mentions that clinical trials are already testing supplements (like Nicotinamide) to boost this energy pathway in glaucoma patients.
TRIOBP: This gene acts like the scaffolding or the steel beams inside a building. It helps organize the structure of the cell. The study suggests that having a strong version of this gene helps keep the "tire rim" wide and strong, even if the pressure inside the eye fluctuates.

The Limitations (The Fine Print)

The paper is honest about what it didn't do:

The "European" Filter: The study only looked at people of European ancestry. It's like testing a car engine only on a specific type of road; we don't know if these same genetic rules apply to people with different backgrounds.
Not a Cure Yet: This study is a map, not a destination. It tells us where to look for the problem, but it doesn't yet offer a new drug. It simply identifies the genes that scientists should study next to build those drugs.

Summary

In short, this paper is a massive genetic map of the optic nerve. It discovered that the nerve has different "zones" controlled by different genes. Crucially, it found that some of these genes protect the nerve from breaking down regardless of eye pressure. This suggests that in the future, we might be able to treat glaucoma not just by lowering pressure, but by fixing the "battery charger" (NMNAT2) or the "scaffolding" (TRIOBP) inside the nerve cells themselves.

Technical Summary: Uncovering the Genetic Architecture of Optic Nerve Integrity Estimates through Genome-wide Association Study Meta-analyses

Problem Statement
Glaucoma is a leading cause of irreversible vision loss, characterized by the progressive atrophy of retinal ganglion cells (RGCs). While intraocular pressure (IOP) is the primary modifiable risk factor, current treatments focusing solely on IOP reduction fail to reverse existing damage or halt progression in many patients. This suggests a need for neuroprotective interventions targeting the intrinsic vulnerability of the optic nerve. Previous genetic studies have largely focused on IOP and vertical cup-to-disc ratio (VCDR), a subjective clinical measure. There is a critical gap in understanding the genetic architecture of more precise, objective biomarkers of optic nerve health: peripapillary retinal nerve fiber layer (pRNFL) thickness and Bruch's membrane opening-minimum rim width (BMO-MRW), measured via Optical Coherence Tomography (OCT).

Methodology
The authors conducted the first genome-wide association study (GWAS) meta-analyses for global and sectoral pRNFL thickness and BMO-MRW using data from the International Glaucoma Genetics Consortium (IGGC).

Cohorts: The study included up to 25,942 European participants for global pRNFL and 12,080 for global BMO-MRW. Sectoral analyses included up to 19,763 individuals for pRNFL.
Phenotypes: Primary phenotypes were global pRNFL thickness and global BMO-MRW. Secondary phenotypes included sectoral measurements (nasal, temporal, superonasal, superotemporal, inferonasal, inferotemporal) and BMO area.
Genetic Analysis: Standardized GWAS were performed in individual cohorts using linear regression adjusted for age, sex, principal components, OCT model, and axial length/spherical equivalent. Fixed-effect meta-analyses were conducted using METAL.
Advanced Analyses:
- Conditional Analysis: The multi-trait-based conditional and joint association analysis (mtCOJO) was used to identify loci independent of IOP and VCDR.
- Gene and Pathway Mapping: mBAT-combo was used for gene-based association, and MAGMA for pathway enrichment.
- Causal Gene Prioritization: Transcriptome-wide association studies (TWAS) were performed using blood (eQTLGen) and retinal (EyeGEx) tissue data, followed by colocalization analysis to identify shared causal variants.
- Genetic Correlation & Causality: LD score regression (LDSC) estimated genetic correlations with glaucoma, IOP, and VCDR. Two-sample Mendelian Randomization (MR) tested the causal effect of IOP on the structural phenotypes.

Key Contributions and Results

Novel Loci Identification: The study identified 9 genome-wide significant loci for global pRNFL thickness and 9 for global BMO-MRW. Furthermore, sectoral analyses revealed 28 independent loci for pRNFL sectors and 19 for BMO-MRW sectors.
Sector-Specific Genetic Architecture: The analysis highlighted significant genetic heterogeneity across retinal sectors. Notably, a locus near the SIX6 gene on chromosome 14 showed genome-wide significance in four pRNFL sectors (temporal, superotemporal, inferonasal, inferotemporal) but was absent in the global pRNFL analysis due to opposing effect sizes between temporal and nasal regions. Similarly, specific variants near RPE65 and HSPA12A showed sector-specific significance for BMO-MRW.
IOP-Independent Genetic Signals: Conditioning on IOP revealed that most loci associated with pRNFL and BMO-MRW remain significant, indicating these traits are not solely driven by IOP but possess an intrinsic neurodegenerative component.
Candidate Causal Genes: TWAS and colocalization analyses prioritized several genes with robust associations independent of IOP:
- For pRNFL: MRPL48, TUBA1C, and NMNAT2.
- For BMO-MRW: PBLD, TRIOBP, H1F0, and HAUS4.
- NMNAT2 and TRIOBP were highlighted as having robust associations with both phenotypes, suggesting potential therapeutic targets.
Causal Inference: MR analysis confirmed a significant causal effect of IOP on both pRNFL thinning and BMO-MRW thinning, with the effect size on BMO-MRW being significantly larger than on pRNFL.
Genetic Correlations: Global BMO-MRW showed a very strong genetic correlation with glaucoma ( $r_g = -0.689$ ) and VCDR ( $r_g = -0.981$ ). Global pRNFL showed a moderate inverse correlation with glaucoma ( $r_g = -0.237$ ) and VCDR ( $r_g = -0.231$ ), but a weaker correlation with IOP.

Significance and Claims
The authors claim that this study elucidates the genetic basis of glaucoma endophenotypes, distinguishing between IOP-driven mechanical damage and intrinsic optic nerve vulnerability. By identifying loci and genes (such as NMNAT2 and TRIOBP) that act independently of IOP, the findings provide a foundation for developing neuroprotective strategies that could halt RGC loss even when IOP is controlled. The study also underscores the importance of analyzing sectoral data, as global averages can mask sector-specific genetic effects (e.g., the SIX6 signal). The authors conclude that these novel loci and prioritized genes serve as a base for future investigations into neuroprotective drug targets for glaucoma.

Limitations Noted by Authors
The study acknowledges limitations including the restriction to individuals of European ancestry, which limits generalizability; reduced statistical power for sectoral analyses compared to global phenotypes; and the need for further functional analysis to validate the identified neuroprotective targets.